Biomarkers of Asthma: Recent Patents from 2009-2011
This review informs on current literature on patents for biomarkers for asthma from 2009 to 2011. Variable airflow obstruction in asthma is generally triggered by gene-environment interactions that can lead to key symptoms of cough, shortness of breath, chest tightness, and wheezing. The episodic an...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | text |
Published: |
Archīum Ateneo
2012
|
Subjects: | |
Online Access: | https://archium.ateneo.edu/chemistry-faculty-pubs/13 http://www.eurekaselect.com/94950/article |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Ateneo De Manila University |
id |
ph-ateneo-arc.chemistry-faculty-pubs-1012 |
---|---|
record_format |
eprints |
spelling |
ph-ateneo-arc.chemistry-faculty-pubs-10122020-06-08T11:04:53Z Biomarkers of Asthma: Recent Patents from 2009-2011 Olmos-Dela Cruz, Ma. Henrietta Macahig, Rene Angelo S Terrado, Mailyn M Lee Yu, Henson L Guidote, Armando M, Jr Quirino, Joselito P This review informs on current literature on patents for biomarkers for asthma from 2009 to 2011. Variable airflow obstruction in asthma is generally triggered by gene-environment interactions that can lead to key symptoms of cough, shortness of breath, chest tightness, and wheezing. The episodic and variable degrees of airway hyperresponsiveness arise from a variety of inflammatory pathways that can make diagnosis and management difficult. Standard pulmonary function tests used for the diagnosis of asthma may fail to predict individual responses to the standard bronchodilator and corticosteroid therapies. Phenotypic predispositions can alter the severity of the asthmatic condition and treatment response. Biomarkers from sputum, exhaled gases, exhaled breath condensates, urine, serum, and broncheolaveolar fluid lavage proteins are currently explored to provide objective metrics for identifying individuals at risk, provide therapy guidance, monitor disease progression and evaluate response to therapy, as a supplement to standard pulmonary function tests. Updates on the refinement of technologies, inherent limitations and benefits of these biomarkers are discussed to provide insights on how current understanding of pathologic mechanisms has been applied to provide information for addressing gaps in the diagnosis and management of asthma. 2012-01-01T08:00:00Z text https://archium.ateneo.edu/chemistry-faculty-pubs/13 http://www.eurekaselect.com/94950/article Chemistry Faculty Publications Archīum Ateneo Asthma biomarkers diagnosis metabolites proteins small molecules EXHALED BIOMARKERS SERUM INFLAMMATORY BIOMARKERS Mast Cell Stability BRONCHOALVEOLAR LAVAGE PROTEINS Chemistry |
institution |
Ateneo De Manila University |
building |
Ateneo De Manila University Library |
continent |
Asia |
country |
Philippines Philippines |
content_provider |
Ateneo De Manila University Library |
collection |
archium.Ateneo Institutional Repository |
topic |
Asthma biomarkers diagnosis metabolites proteins small molecules EXHALED BIOMARKERS SERUM INFLAMMATORY BIOMARKERS Mast Cell Stability BRONCHOALVEOLAR LAVAGE PROTEINS Chemistry |
spellingShingle |
Asthma biomarkers diagnosis metabolites proteins small molecules EXHALED BIOMARKERS SERUM INFLAMMATORY BIOMARKERS Mast Cell Stability BRONCHOALVEOLAR LAVAGE PROTEINS Chemistry Olmos-Dela Cruz, Ma. Henrietta Macahig, Rene Angelo S Terrado, Mailyn M Lee Yu, Henson L Guidote, Armando M, Jr Quirino, Joselito P Biomarkers of Asthma: Recent Patents from 2009-2011 |
description |
This review informs on current literature on patents for biomarkers for asthma from 2009 to 2011. Variable airflow obstruction in asthma is generally triggered by gene-environment interactions that can lead to key symptoms of cough, shortness of breath, chest tightness, and wheezing. The episodic and variable degrees of airway hyperresponsiveness arise from a variety of inflammatory pathways that can make diagnosis and management difficult. Standard pulmonary function tests used for the diagnosis of asthma may fail to predict individual responses to the standard bronchodilator and corticosteroid therapies. Phenotypic predispositions can alter the severity of the asthmatic condition and treatment response. Biomarkers from sputum, exhaled gases, exhaled breath condensates, urine, serum, and broncheolaveolar fluid lavage proteins are currently explored to provide objective metrics for identifying individuals at risk, provide therapy guidance, monitor disease progression and evaluate response to therapy, as a supplement to standard pulmonary function tests. Updates on the refinement of technologies, inherent limitations and benefits of these biomarkers are discussed to provide insights on how current understanding of pathologic mechanisms has been applied to provide information for addressing gaps in the diagnosis and management of asthma. |
format |
text |
author |
Olmos-Dela Cruz, Ma. Henrietta Macahig, Rene Angelo S Terrado, Mailyn M Lee Yu, Henson L Guidote, Armando M, Jr Quirino, Joselito P |
author_facet |
Olmos-Dela Cruz, Ma. Henrietta Macahig, Rene Angelo S Terrado, Mailyn M Lee Yu, Henson L Guidote, Armando M, Jr Quirino, Joselito P |
author_sort |
Olmos-Dela Cruz, Ma. Henrietta |
title |
Biomarkers of Asthma: Recent Patents from 2009-2011 |
title_short |
Biomarkers of Asthma: Recent Patents from 2009-2011 |
title_full |
Biomarkers of Asthma: Recent Patents from 2009-2011 |
title_fullStr |
Biomarkers of Asthma: Recent Patents from 2009-2011 |
title_full_unstemmed |
Biomarkers of Asthma: Recent Patents from 2009-2011 |
title_sort |
biomarkers of asthma: recent patents from 2009-2011 |
publisher |
Archīum Ateneo |
publishDate |
2012 |
url |
https://archium.ateneo.edu/chemistry-faculty-pubs/13 http://www.eurekaselect.com/94950/article |
_version_ |
1728621324580945920 |